{"id":"https://openalex.org/W1970125713","doi":"https://doi.org/10.1185/03007990903178735","title":"Effect of saxagliptin monotherapy in treatment-na\u00efve patients with type 2 diabetes","display_name":"Effect of saxagliptin monotherapy in treatment-na\u00efve patients with type 2 diabetes","publication_year":2009,"publication_date":"2009-08-04","ids":{"openalex":"https://openalex.org/W1970125713","doi":"https://doi.org/10.1185/03007990903178735","mag":"1970125713","pmid":"https://pubmed.ncbi.nlm.nih.gov/19650754"},"language":"en","primary_location":{"id":"doi:10.1185/03007990903178735","doi":"https://doi.org/10.1185/03007990903178735","is_oa":false,"landing_page_url":"https://doi.org/10.1185/03007990903178735","pdf_url":null,"source":{"id":"https://openalex.org/S206643269","display_name":"Current Medical Research and Opinion","issn_l":"0300-7995","issn":["0300-7995","1473-4877"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medical Research and Opinion","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045489578","display_name":"Julio Rosenstock","orcid":"https://orcid.org/0000-0001-8324-3275","observed_orcids":["https://orcid.org/0000-0001-8324-3275"]},"institutions":[{"id":"https://openalex.org/I2800474951","display_name":"Medical City Dallas Hospital","ror":"https://ror.org/059rc1n32","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800474951"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J. Rosenstock","raw_affiliation_strings":["Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA","Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, C-685, Dallas, TX 75230, USA. juliorosenstock@dallasdiabetes.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA","institution_ids":["https://openalex.org/I2800474951"]},{"raw_affiliation_string":"Dallas Diabetes and Endocrine Center at Medical City, 7777 Forest Lane, C-685, Dallas, TX 75230, USA. juliorosenstock@dallasdiabetes.com","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005019504","display_name":"Carlos Alberto Aguilar-Salinas","orcid":"https://orcid.org/0000-0001-8517-0241","observed_orcids":["https://orcid.org/0000-0001-8517-0241"]},"institutions":[{"id":"https://openalex.org/I4210097900","display_name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","ror":"https://ror.org/00xgvev73","country_code":"MX","type":"facility","lineage":["https://openalex.org/I4210095685","https://openalex.org/I4210097900","https://openalex.org/I4210128723"]}],"countries":["MX"],"is_corresponding":false,"raw_author_name":"C. Aguilar-Salinas","raw_affiliation_strings":["Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n, Mexico City, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n, Mexico City, Mexico","institution_ids":["https://openalex.org/I4210097900"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047160563","display_name":"ERIC J. KLEIN","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Klein","raw_affiliation_strings":["Capital Clinical Research Center, Olympia, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Capital Clinical Research Center, Olympia, WA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Nepal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I20089843","display_name":"Princeton University","ror":"https://ror.org/00hx57361","country_code":"US","type":"education","lineage":["https://openalex.org/I20089843"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Nepal","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I20089843","https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111609755","display_name":"James F. List","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I20089843","display_name":"Princeton University","ror":"https://ror.org/00hx57361","country_code":"US","type":"education","lineage":["https://openalex.org/I20089843"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. List","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I20089843","https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090807290","display_name":"R. Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I20089843","display_name":"Princeton University","ror":"https://ror.org/00hx57361","country_code":"US","type":"education","lineage":["https://openalex.org/I20089843"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Chen","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I20089843","https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":null,"display_name":"for the CV181-011 Study Investigators","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"for the CV181-011 Study Investigators","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5045489578"],"corresponding_institution_ids":["https://openalex.org/I2800474951"],"apc_list":null,"apc_paid":null,"fwci":26.0177,"has_fulltext":false,"cited_by_count":285,"citation_normalized_percentile":{"value":0.99769829,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"25","issue":"10","first_page":"2401","last_page":"2411"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/saxagliptin","display_name":"saxagliptin","score":0.9950000047683716},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9350000023841858},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.8659999966621399},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.9269999861717224},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7559999823570251},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8849999904632568},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9819999933242798},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.9879999756813049},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.9800000190734863},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5109999775886536}],"concepts":[{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.9894589185714722},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9236558675765991},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.7683420181274414},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.6851192712783813},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.636482834815979},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6336420774459839},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6266586780548096},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.5275048017501831},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5196431875228882},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44079554080963135},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4006744623184204},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3493337035179138},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.33607202768325806},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.30106860399246216},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.15042081475257874},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.09223055839538574},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004151","descriptor_name":"Dipeptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004151","descriptor_name":"Dipeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1185/03007990903178735","doi":"https://doi.org/10.1185/03007990903178735","is_oa":false,"landing_page_url":"https://doi.org/10.1185/03007990903178735","pdf_url":null,"source":{"id":"https://openalex.org/S206643269","display_name":"Current Medical Research and Opinion","issn_l":"0300-7995","issn":["0300-7995","1473-4877"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medical Research and Opinion","raw_type":"journal-article"},{"id":"pmid:19650754","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19650754","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current medical research and opinion","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320306089","display_name":"American Diabetes Association","ror":"https://ror.org/04f6cgz95"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1968236091","https://openalex.org/W1971471384","https://openalex.org/W2012437459","https://openalex.org/W2032322539","https://openalex.org/W2038915028","https://openalex.org/W2069794993","https://openalex.org/W2084948079","https://openalex.org/W2085862152","https://openalex.org/W2089095955","https://openalex.org/W2117343153","https://openalex.org/W2127277443","https://openalex.org/W2133795831","https://openalex.org/W2154615287","https://openalex.org/W2159205789","https://openalex.org/W2160234571"],"related_works":["https://openalex.org/W2150483909","https://openalex.org/W2126065052","https://openalex.org/W7099969347","https://openalex.org/W2164282118","https://openalex.org/W1605983684","https://openalex.org/W2512797700","https://openalex.org/W2103058881","https://openalex.org/W3030900679","https://openalex.org/W2045063167","https://openalex.org/W2217788221"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,145,300,306,345,352,355,363,377],"efficacy":[4],"and":[5,19,43,48,65,77,122,171,199,244,258,285,293,354,395],"safety":[6],"of":[7,116,319,347,357,379,403],"once-daily":[8],"saxagliptin":[9,52,83,147,168,196,241,255,279,386],"monotherapy":[10,387],"in":[11,110,124,152,299,332,400],"treatment-na\u00efve":[12],"patients":[13,37,73,117,220,368],"with":[14,35,50,71,140,274,323,339],"type":[15],"2":[16],"diabetes":[17],"(T2D)":[18],"inadequate":[20],"glycemic":[21,404],"control.":[22],"RESEARCH":[23],"DESIGN":[24],"AND":[25],"METHODS:":[26],"This":[27],"study":[28,315],"included":[29,103,344],"a":[30,66,348],"main":[31],"treatment":[32],"cohort":[33,69],"(MTC)":[34],"401":[36],"(HbA(1c)":[38,74],">":[39,75],"or":[40,45,55,60,79,327],"=":[41,209,212,230,234,238,283],"7%":[42,224],"<":[44,78,120,181,215,223,289,326],"=10%)":[46],"randomized":[47,374],"treated":[49],"oral":[51],"2.5,":[53,169,197,242,256],"5,":[54,170,198,243,257],"10":[56,84,172,200,245,259,286],"mg":[57,85,260,264,271,281,287],"once":[58,86],"daily":[59,87],"placebo":[61,178,207,249,269],"for":[62,88,131,167,177,195,206,240,254,278,351,388],"24":[63,89,109,163,227,303,389],"weeks":[64,390],"separate":[67],"open-label":[68],"(OLC)":[70],"66":[72],"10%":[76],"=12%)":[80],"who":[81],"received":[82],"weeks.":[90,304],"Primary":[91],"endpoint":[92],"was":[93,186,252,311,336,391],"HbA(1c)":[94,119,155,222],"change":[95,104],"from":[96,105,157,189],"baseline":[97,106,158,190],"to":[98,107,161],"week":[99,108,162,226],"24.":[100],"Secondary":[101],"endpoints":[102],"fasting":[111],"plasma":[112],"glucose":[113,126,325],"(FPG),":[114],"proportion":[115],"achieving":[118],"7%,":[121],"changes":[123,156],"postprandial":[125],"area-under-the-curve":[127],"(PPG-AUC).":[128],"Efficacy":[129],"analyses":[130],"continuous":[132],"variables":[133],"were":[134,296,330],"performed":[135],"using":[136],"an":[137],"ANCOVA":[138],"model":[139],"last-observation-carried-forward":[141],"methodology.":[142],"RESULTS:":[143],"In":[144,305],"MTC,":[146,307],"demonstrated":[148,277,396],"statistically":[149],"significant":[150],"decreases":[151],"adjusted":[153],"mean":[154,184],"(mean,":[159],"7.9%)":[160],"(-0.43%,":[164],"-0.46%,":[165],"-0.54%)":[166],"mg,":[173,201,246],"respectively,":[174,202,247],"vs.":[175,203,268,406],"+0.19%":[176],"(all":[179],"p":[180,211,214],"0.0001).":[182,290],"Adjusted":[183],"FPG":[185],"significantly":[187],"reduced":[188,253],"(-15,":[191],"-9,":[192],"-17":[193],"mg/dL)":[194,329],"+6":[204],"mg/dL":[205],"(p":[208,282,288],"0.0002,":[210],"0.0074,":[213],"0.0001,":[216],"respectively).":[217],"More":[218],"saxagliptin-treated":[219],"achieved":[221],"at":[225,302],"(35%":[228],"[p":[229,233,237],"NS],":[231],"38%":[232],"0.0443],":[235],"41%":[236],"0.0133])":[239],"than":[248],"(24%).":[250],"PPG-AUC":[251,294],"(-6868,":[261],"-6896,":[262],"-8084":[263],"x":[265,272],"min/dL,":[266],"respectively)":[267],"(-647":[270],"min/dL)":[273],"statistical":[275],"significance":[276],"5":[280],"0.0002)":[284],"HbA(1c),":[291],"FPG,":[292],"reductions":[295,399],"also":[297],"observed":[298,331],"OLC":[301,353],"adverse":[308],"event":[309],"frequency":[310],"similar":[312],"across":[313],"all":[314],"arms.":[316],"No":[317],"cases":[318],"confirmed":[320],"hypoglycemia":[321],"(symptoms,":[322],"fingerstick":[324],"=50":[328],"either":[333],"cohort.":[334],"Saxagliptin":[335],"not":[337],"associated":[338],"weight":[340],"gain.":[341],"Study":[342],"limitations":[343],"lack":[346],"control":[349,405],"group":[350],"use":[356],"prespecified":[358],"rescue":[359,382],"criteria,":[360],"which":[361,367],"limited":[362],"exposure":[364],"time":[365],"during":[366],"could":[369],"remain":[370],"on":[371],"their":[372],"originally":[373],"medication":[375],"without":[376],"introduction":[378],"additional":[380],"antihyperglycemic":[381],"treatment.":[383],"CONCLUSIONS:":[384],"Once-daily":[385],"generally":[392],"well":[393],"tolerated":[394],"clinically":[397],"meaningful":[398],"key":[401],"parameters":[402],"placebo.":[407],"TRIAL":[408],"REGISTRATION:":[409],"Clinical":[410],"Trials":[411],"NCT00121641":[412]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":15},{"year":2016,"cited_by_count":22},{"year":2015,"cited_by_count":22},{"year":2014,"cited_by_count":33},{"year":2013,"cited_by_count":24},{"year":2012,"cited_by_count":26}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}